Self-Study Sample Clauses

Self-Study. (second, third and fourth years only) Each faculty member will prepare a self-study using the approved format as described in Appendix E and provide copies to all review team members by the sixth (6th) week of the semester of the review.
AutoNDA by SimpleDocs
Self-Study. The faculty member under review will submit a self-study as in Procedure A.
Self-Study. Each faculty member will prepare a self-study using the approved format, as described in Appendix E, and provide copies to all review team members on a mutually agreed to date determined in the pre-review arrangements in Section “a” above. The self-study shall address “as defined in Section 4.1.3.” (See Sections 8.4.1.15, 8.4.2.9, 8.4.3.15, 8.4.4.16, and 8.4.5.8).
Self-Study. Each faculty member will prepare a self-study using the approved format, as described in Appendix F, and provide copies to all review team members on a mutually agreed to date determined in the pre-review arrangements in Section “a” above. The self-study is not required of adjunct faculty in their first year of review.
Self-Study. Resident shall develop a personal program of self-study and professional growth with guidance from the teaching staff.
Self-Study. The Permanence is a working period during which the pupil studies independently, and is a key to success at school. During self-studies, everyone works peacefully.
Self-Study. A self-study for the teaching element shall only be required if the previous evaluation of the teaching assignment contained recommendations. If required, the self-study can be limited to a response to the recommendations. (Referenced above in 8.15.1).
AutoNDA by SimpleDocs
Self-Study. The TFM shall complete a succinct, 3 to 5-page, self-study describing how they have met each of the five Criteria for Evaluation specified in section H.1.4. in the performance of their job functions. While those being evaluated must address each of the five major criteria in each evaluation cycle, faculty members may provide a distinctive means of emphasis on the various elements contained under each of the five
Self-Study. The districts will pay eight (8) hours beyond the regular contract to each employee to be used for completing a self-study. After the employee has completed the self-study, if any of the eight (8) hours remain, the remaining time can be used for curriculum work. The building principal must authorize the use of hours. The Districts and GPEA agree that before these hours can be used, we will dedicate one board waiver day (8 hours) to completing the self-study. The Districts and GPEA agree that, if the State Board of Education agrees, we will use 8 hours in three after school or evening sessions. The 8 hours of extra pay for curriculum work will be a mutually agreed upon negotiated item between the Districts and GPEA for the 2002-2003 school year. (Negotiated 2000 - 2001 buy dated.)

Related to Self-Study

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Re-Study If Re-Study of the Interconnection Facilities Study is required due to a higher queued project dropping out of the queue or a modification of a higher queued project pursuant to Section 4.4, Transmission Provider shall so notify Interconnection Customer in writing. Such Re-Study shall take no longer than sixty (60) Calendar Days from the date of notice. Any cost of Re-Study shall be borne by the Interconnection Customer being re-studied.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Trials The Ship shall run the following test and trials:

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Independent Study Independent study is a program of independent study, research, and/or experience directly related to the duties described in the employee’s job description or related classification as determined by the Retraining and Study Committee, which promises professional values equivalent to that derived from formal study at a recognized educational institution.

Time is Money Join Law Insider Premium to draft better contracts faster.